Global Cord Blood (CO) Competitors $0.75 -0.25 (-25.00%) As of 10/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CO vs. MRAI, CORBF, IZTC, IPA, ATRA, FONR, HOWL, ADVM, OBIO, and PLRXShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Marpai (MRAI), Global Cord Blood (CORBF), Invizyne Technologies (IZTC), ImmunoPrecise Antibodies (IPA), Atara Biotherapeutics (ATRA), Fonar (FONR), Werewolf Therapeutics (HOWL), Adverum Biotechnologies (ADVM), Orchestra BioMed (OBIO), and Pliant Therapeutics (PLRX). Global Cord Blood vs. Its Competitors Marpai Global Cord Blood Invizyne Technologies ImmunoPrecise Antibodies Atara Biotherapeutics Fonar Werewolf Therapeutics Adverum Biotechnologies Orchestra BioMed Pliant Therapeutics Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CO) are both small-cap miscellaneous health & allied services, not elsewhere classified industry companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Which has preferable earnings and valuation, MRAI or CO? Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarpai$34.87M0.81-$28.75M-$0.87-1.78Global Cord Blood$1.24B0.07$79.04M$0.641.17 Is MRAI or CO more profitable? Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Marpai-85.70% N/A -100.23% Global Cord Blood N/A N/A N/A Which has more risk and volatility, MRAI or CO? Marpai has a beta of 4.6, indicating that its stock price is 360% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MRAI or CO? 49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor MRAI or CO? In the previous week, Global Cord Blood had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Global Cord Blood and 1 mentions for Marpai. Global Cord Blood's average media sentiment score of 0.45 beat Marpai's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marpai 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Global Cord Blood 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGlobal Cord Blood beats Marpai on 8 of the 12 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CO vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$91.16M$70.17M$6.11B$21.95BDividend YieldN/AN/A5.51%3.56%P/E Ratio1.170.5985.7229.65Price / Sales0.070.45580.63100.18Price / Cash4.192.8026.3018.33Price / Book0.120.1213.234.61Net Income$79.04M$43.11M$3.30B$1.01B7 Day PerformanceN/A-12.50%4.85%0.14%1 Month Performance-28.57%-14.07%8.50%2.28%1 Year Performance-57.14%25.43%87.78%13.86% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGlobal Cord BloodN/A$0.75-25.0%N/A-42.9%$91.16M$1.24B1.171,202Gap DownMRAIMarpaiN/A$1.31+19.1%N/A+170.0%$20.14M$34.87M-0.50150News CoverageGap UpHigh Trading VolumeCORBFGlobal Cord BloodN/A$1.00+400.0%N/A-57.1%$121.55M$196.12M0.001,200Gap DownIZTCInvizyne TechnologiesN/A$15.48+6.3%N/AN/A$96.78MN/A0.0029Gap UpIPAImmunoPrecise Antibodies1.1213 of 5 stars$2.10+8.5%$4.00+90.9%+235.2%$96.68M$17.59M-3.0880Gap UpATRAAtara Biotherapeutics4.5667 of 5 stars$13.81+0.5%$21.00+52.1%+81.8%$96.50M$188.67M-32.12330FONRFonar0.8506 of 5 stars$15.15-1.4%N/A-1.2%$95.29M$104.35M12.32480Positive NewsHOWLWerewolf Therapeutics3.1484 of 5 stars$2.19+5.8%$8.00+265.3%+0.0%$94.66M$1.88M-1.3440Gap UpHigh Trading VolumeADVMAdverum Biotechnologies3.9488 of 5 stars$4.60+2.0%$19.75+329.3%-29.6%$94.64M$1M-0.59190OBIOOrchestra BioMed2.9768 of 5 stars$2.46+1.7%$13.50+448.8%-44.4%$93.52M$2.64M-1.344PLRXPliant Therapeutics3.8182 of 5 stars$1.49-2.0%$8.19+449.5%-87.1%$93.31M$1.58M-0.4490 Related Companies and Tools Related Companies MRAI Competitors CORBF Competitors IZTC Competitors IPA Competitors ATRA Competitors FONR Competitors HOWL Competitors ADVM Competitors OBIO Competitors PLRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
